Posts Tagged ‘ASTM’

ASTM up, GE with bright volume, ESI falters

Monday, January 10th, 2011

Aastrom Biosciences Inc. (Nasdaq: ASTM) shares gained 22.7 percent to $3.19 Monday. Volume of 8,380,362 shares was more than 3 1/2 times its usual volume. The company will be presenting Phase 2 Surgical-DCM six-month results sometime this month.

General Electric Company (NYSE: GE) traded in 51,542,124 shares Monday afternoon, just shy of its daily average of 57,051,500. Prices for GE inched up 0.7 percent to $18.56. GE Energy Financial Services, and Bankers Commercial Corporation, a unit of UnionBanCal Corporation, announced today that they have purchased the first wind farm to start operations in one of the largest wind energy projects in the United States.

ITT Educational Services, Inc. (NYSE: ESI) dipped 12.3 percent Monday to $56.62. Volume for the stock of 1,899,031 shares doubled its daily average, and then some. ESI is a leading provider of post-secondary degree programs.

EX excels, SIRI dishes widely, ASTM falls

Thursday, November 18th, 2010

Exelixis Inc. (NasdaqGS: EXEL) improved in price by 29.66 percent in Thursday afternoon trade to $6.12 Volume of 11,806,150 shares proved about 12 times the stock’s three-month daily average. The drug maker Thursday reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

Sirius XM Radio Inc. (NasdaqGS: SIRI) was a volume leader Thursday afternoon, with 47,602,492 shares changing hands, against its usual daily volume of 75,126,200 shares. SIRI shares added 3.70 percent Thursday in price to $1.40.

Aastrom Biosciences Inc. (NasdaqCM: ASTM) fell in price Thursday by 22.14 percent to $3.27. Volume of 4,182,850 shares trampled over usual daily volume of 1,068,090 shares. The Michigan-based developer of expanded autologous cellular therapies today announced that an interim analysis of all 86 patients enrolled in the company’s Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.

ISLN spikes, QQQQ among volume leaders, ASTM ailing

Monday, November 15th, 2010

Isilon Systems Inc. (NasdaqGM: ISLN) enjoyed a profitable day Monday, jumping 28.45 percent in price to close at $33.77. Volume in ISLN was 35,703,591 shares, compared to a daily average of just over one million. On Monday, EMC Corp. said it has signed a $2.25 billion deal to acquire Isilon Systems Inc. in yet another step in the consolidation of the increasingly important data-storage industry.

PowerShares QQQ (NasdaqGM: QQQQ) traded widely Monday in 56,163,936 shares. The figure was still below its three-month daily average of 73,899,700. The stock suffered in price, though, 0.37 percent to $52.31.

Aastrom Biosciences Inc. (NasdaqCM: ASTM) fell in price Monday’s trading by 15.48 percent to $3.55. Volume in ASTM was 4,168,049, or about four times its normal daily average. The Ann Arbor, Mich.-based company is a leading developer of expanded autologous cellular therapies for the treatment of severe cardiovascular diseases.